(Q43001742)

12 November 2017

title

Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a. (English)

1 reference

12 November 2017

1 reference

1 reference

Y Q Zhou

1

1 reference

12 November 2017

X H Wang

2

1 reference

12 November 2017

G H Hong

3

1 reference

12 November 2017

Y Zhu

4

1 reference

12 November 2017

X Q Zhang

5

1 reference

12 November 2017

Y J Hu

6

1 reference

12 November 2017

Q Mao

7

1 reference

12 November 2017

publication date

24 November 2010

1 reference

Journal of Viral Hepatitis

12 November 2017

published in

1 reference

12 November 2017

volume

18

1 reference

12 November 2017

issue

8

1 reference

12 November 2017

page(s)

595-600

1 reference

The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

What is the safe duration of therapy for patients infected with HCV genotype 6?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Hepatitis C virus genotype distribution in Myanmar: Predominance of genotype 6 and existence of new genotype 6 subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Identification of hepatitis C virus genotype 6 in Korean patients by analysis of 5' untranslated region using a matrix assisted laser desorption/ionization time of flight-based assay, restriction fragment mass polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: Full-length sequences of two new subtype 6w strains and a recombinant form_2b6w

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Changes in modes of hepatitis C infection acquisition and genotypes in southwest China

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01373.X

10.1111/J.1365-2893.2010.01373.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference